The report "Superdisintegrants Market by Product (Modified Starch, Modified Cellulose, Crospovidone, Ion Exchange Resin), Formulation (Tablet, Capsules), Therapeutic Area (Gastrointestinal, Cardiovascular, Neurology, Oncology, Hematology) - Global Forecast to 2023", The superdisintegrants market is expected to reach USD 536.5 million by 2023 from an estimated USD 366.4 million in 2018, at a CAGR of 7.9%. The major factors driving the growth of this market include the increasing adoption of orally disintegrating tablets, growing generics market, and emergence of new superdisintegrants for the pharmaceutical industry.
Browse 124 market data Tables and 37 Figures spread through 182 Pages and in-depth TOC on "Superdisintegrants Market by Product (Modified Starch, Modified Cellulose, Crospovidone, Ion Exchange Resin), Formulation (Tablet, Capsules), Therapeutic Area (Gastrointestinal, Cardiovascular, Neurology, Oncology, Hematology) - Global Forecast to 2023"
Early buyers will receive 10% customization on reports.
By type, the synthetic superdisintegrants segment is estimated to account for the largest share of the superdisintegrants market in 2018
On the basis of type, the synthetic superdisintegrants segment accounted for the largest share of the global superdisintegrants market in 2018. The large share can be attributed to the widespread usage of these superdisintegrants in various pharmaceutical formulations. The advantages associated with synthetic superdisintegrants include their effectiveness at lower concentrations as compared to starch and lesser effect on the compressibility and flowability of the dosage form, which drives their use in various oral dosage formulations.
By formulation, the tablets segment is expected to hold the largest share in 2018
Based on formulation, the superdisintegrants market is segmented into tablets and capsules. In 2018, the tablets segment is estimated to account for the largest share of the superdisintegrants market. Benefits such as stability, low manufacturing cost (as compared to other dosage forms), easy product identification, and compactness are driving the production of tablet formulations. The increasing focus on fast and orally disintegrating tablets is also contributing to the large share of this segment.
By therapeutic area, the neurological diseases segment is expected to hold the largest share of the superdisintegrants market in 2018
On the basis of therapeutic area, the superdisintegrants market is segmented into gastrointestinal diseases, neurological diseases, oncology, infectious diseases, cardiovascular disease, hematological diseases, and inflammatory diseases. The neurological diseases segment is estimated to account for the largest share in 2018. The increasing incidences of neurological disorders has led to an increase in the demand for effective therapies, which has further led to the increasing use of ODTs in the treatment of neurological disorders.
Europe expected to dominate the market in 2018
Europe is expected to account for the largest share of the superdisintegrants market in 2018, followed by North America and Asia Pacific. The large share of this region can be attributed to the presence of a number of pharmaceutical giants with large production capacities leading to high consumption of excipients. The growing emphasis on superior pharmaceutical products and generics is also expected to aid the market growth in the region. Moreover, a number of major global players are based in Germany.
The prominent players in the global superdisintegrants market are Ashland Inc. (US), BASF SE (Germany), DowDuPont (US), JRS Pharma (Germany), DFE Pharma (Germany), Roquette Freres (France), Asahi Kasei Corporation (Japan), Merck KGaA (Germany), Corel Pharma Chem (India), and Avantor Performance Materials, LLC (US).
Don’t miss out on business opportunities in Superdisintegrants Market. Speak to our analyst and gain crucial industry insights that will help your business grow.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441